Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

By J. Nutt, K. Burchiel, C. Comella, J. Jankovic, A. Lang, E. Laws, Andres M. Lozano, R. Penn, R. Simpson, M. Stacy and 31 more. Neurology, 2003

827 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Past, Present, and Future of Parkinson’s Disease: A Special Essay on the 200th Anniversary of the Shaking Palsy (2017, neutral): “The preclinical data supporting this delivery approach was limited,(277) and this trial reported no efficacy or significant side effects.(278) A patient who came to autopsy failed to demonstrate any dopamine regeneration, likely a result of poor penetration of the trophic factor from the ventricular”
The subthalamic nucleus in the context of movement disorders. (2004, neutral): “…of the STN (Bergman et al., 1990; Aziz et al., 1991; Klockgether et al., 1991; Wichmann et al., 1994b; Limousin et al., 1995; Hutchison et al., 1998; Vila et al., 1999; Benabid et al., 2000a,b; Blandini et al., 2001; Levy et al., 2001; Luo et al., 2002; Gill et al., 2003; Nutt et al., 2003).”
GDNF, NGF and BDNF as therapeutic options for neurodegeneration. (2013, background): “In 2003 the results were reported of a randomised double-blind placebo-controlled trial of intracerebroventricular (ICV) infusion of GDNF (Nutt et al., 2003).”
Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease (2006, background): “Catheter Misplacement/migration from Ipu target 2 (6) 3 (4)”